Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUREA: Atezolizumab + Split-Dose Cisplatin/Gemcitabine in Urothelial Carcinoma
NCT04602078Phase 2Completed
- Sponsor
- SOGUG
- Start
- Dec 2020
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in urothelial carcinoma (UC), sponsored by SOGUG. Primary endpoint: Overall Response Rate. Started Dec 2020; status: completed.
02
Drugs
atezolizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04602078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602078.